Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 5
2006 3
2007 3
2009 2
2010 1
2011 1
2013 2
2014 4
2015 4
2016 9
2017 10
2018 10
2019 9
2020 9
2021 8
2022 13
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Results by year

Filters applied: . Clear all
Page 1
DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology.
Rahman R, Shi DD, Reitman ZJ, Hamerlik P, de Groot JF, Haas-Kogan DA, D'Andrea AD, Sulman EP, Tanner K, Agar NYR, Sarkaria JN, Tinkle CL, Bindra RS, Mehta MP, Wen PY. Rahman R, et al. Among authors: bindra rs. Neuro Oncol. 2024 Mar 22:noae072. doi: 10.1093/neuonc/noae072. Online ahead of print. Neuro Oncol. 2024. PMID: 38770568
Intrathecal delivery of nanoparticle PARP inhibitor to the cerebrospinal fluid for the treatment of metastatic medulloblastoma.
Khang M, Lee JH, Lee T, Suh HW, Lee S, Cavaliere A, Rushing A, Geraldo LH, Belitzky E, Rossano S, de Feyter HM, Shin K, Huttner A, Roussel MF, Thomas JL, Carson RE, Marquez-Nostra B, Bindra RS, Saltzman WM. Khang M, et al. Among authors: bindra rs. Sci Transl Med. 2023 Nov;15(720):eadi1617. doi: 10.1126/scitranslmed.adi1617. Epub 2023 Nov 1. Sci Transl Med. 2023. PMID: 37910601 Free PMC article.
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer.
Cecchini M, Zhang JY, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein SM, Kortmansky J, Johung KL, Bindra RS, LoRusso P, Schalper KA. Cecchini M, et al. Among authors: bindra rs. Cancer Res Commun. 2023 Jun 28;3(6):1132-1139. doi: 10.1158/2767-9764.CRC-23-0045. eCollection 2023 Jun. Cancer Res Commun. 2023. PMID: 37387791 Free PMC article.
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma.
Fanucci K, Pilat MJ, Shyr D, Shyr Y, Boerner S, Li J, Durecki D, Drappatz J, Puduvalli V, Lieberman FS, Gonzalez J, Giglio P, Ivy SP, Bindra RS, Omuro A, LoRusso P. Fanucci K, et al. Among authors: bindra rs. Cancer Res Commun. 2023 Feb 2;3(2):192-201. doi: 10.1158/2767-9764.CRC-22-0436. eCollection 2023 Feb. Cancer Res Commun. 2023. PMID: 36968138 Free PMC article. Clinical Trial.
Anti-seed PNAs targeting multiple oncomiRs for brain tumor therapy.
Wang Y, Malik S, Suh HW, Xiao Y, Deng Y, Fan R, Huttner A, Bindra RS, Singh V, Saltzman WM, Bahal R. Wang Y, et al. Among authors: bindra rs. Sci Adv. 2023 Feb 10;9(6):eabq7459. doi: 10.1126/sciadv.abq7459. Epub 2023 Feb 8. Sci Adv. 2023. PMID: 36753549 Free PMC article.
96 results